Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ -- ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab ...
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The collaboration agreement centres around Alchemab’s antibody discovery platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback